Accelerate Diagnostics (AXDX) Reports In-Line Q3 EPS

Accelerate Diagnostics (NASDAQ: AXDX) reported Q3 EPS of ($0.41), in-line with the analyst estimate of ($0.41). Revenue for the quarter came in at $1.36 million versus the consensus estimate of $2.95 million.

For earnings history and earnings-related data on Accelerate Diagnostics (AXDX) click here.

You May Also Be Interested In

• ASML Holdings (ASML) Tops Q2 EPS by 59c; offers guidance
• SCHMID Group raises 2026 order intake guidance to €125-€150M
• Morgan Stanley Assumes Pluxee France SA (PLX:FP) at Equalweight